Kura Oncology Valuation Multiples

Kura Oncology Overview

About Kura Oncology

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Founded

2007

HQ

Employees

192

Website

kuraoncology.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $80M

EBITDA: ($312M)

EV

$135M

Valuation Multiples

Multiples.vc

Start free trial

Kura Oncology Financials

Kura Oncology reported last 12-month revenue of $80M and negative EBITDA of ($312M).

In the same LTM period, Kura Oncology generated $78M in gross profit, ($312M) in EBITDA losses, and had net loss of ($286M).

Kura Oncology P&L

In the most recent fiscal year, Kura Oncology reported revenue of $67M and EBITDA of ($276M).

Kura Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX

Kura Oncology Stock Performance

Kura Oncology has current market cap of $782M, and enterprise value of $135M.

Kura Oncology's stock price is $8.85.

Kura Oncology Valuation Multiples

Kura Oncology trades at 1.7x EV/Revenue multiple, and (0.4x) EV/EBITDA.

Kura Oncology Financial Valuation Multiples

As of April 11, 2026, Kura Oncology has market cap of $782M and EV of $135M.

Equity research analysts estimate Kura Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Kura Oncology has a P/E ratio of (2.7x).

Kura Oncology Margins & Growth Rates

Kura Oncology's revenue in the last 12 month grew by 82%.

Kura Oncology's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $1.9M for the same period.

Kura Oncology's rule of 40 is (237%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Kura Oncology's rule of X is (140%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Kura Oncology Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Kura Oncology M&A Activity

Kura Oncology acquired XXX companies to date.

Last acquisition by Kura Oncology was on XXXXXXXX, XXXXX. Kura Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Kura Oncology Investment Activity

Kura Oncology invested in XXX companies to date.

Kura Oncology made its latest investment on XXXXXXXX, XXXXX. Kura Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).